Please login to the form below

Not currently logged in
Email:
Password:

hypertriglyceridaemia

This page shows the latest hypertriglyceridaemia news and features for those working in and with pharma, biotech and healthcare.

FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

FDA starts speedy review of Lynparza plus Avastin in ovarian cancer

hypertriglyceridaemia. The STRENGTH trial was viewed as being critical to expanding the market for the drug, whose sales hasn’t taken off as AZ had hoped since approval.

Latest news

  • FDA approves AZ’s fish oil drug FDA approves AZ’s fish oil drug

    The FDA approval covers its use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia. ... According to AZ, nearly four million adults in the US currently have severe hypertriglyceridaemia.

  • FDA to review AZ's fish oil drug Epanova FDA to review AZ's fish oil drug Epanova

    The US Food and Drug Administration (FDA) will assess Epanova for use in the treatment of patients with severe hypertriglyceridaemia – an excess of fatty molecules called triglycerides in the blood. ... By tackling triglycerides, these oils can have

  • FDA gives priority review status to BMS/ AZ's metreleptin FDA gives priority review status to BMS/ AZ's metreleptin

    Amylin filed for approval of metreleptin in 2010 as a treatment for diabetes and/or hypertriglyceridaemia in LD patients, using a rolling biologics license application (BLA) that allowed the various parts

  • Amylin and Takeda halt obesity drug study

    In late 2010, Amylin began submission of a rolling US Biologics Licensing Application for metreleptin as monotherapy to treat diabetes and/or hypertriglyceridaemia (high levels of triglycerides in the bloodstream) in

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics